0B68 Yeo, Charles - Thomas Jefferson University - Thomas Jefferson University
Charles J. Yeo, MD, FACS

Charles J. Yeo, MD, FACS

Contact Dr. Yeo

1015 Walnut Street
Curtis Building, Suite 620
Philadelphia, PA 19107

(215) 955-8643
(215) 923-6609 fax

Most Recent Peer-reviewed Publications

  1. Fluid Restriction During Pancreaticoduodenectomy. Is It Effective in Reducing Postoperative Complications?
  2. A prospective, randomized, double-blind, placebo controlled trial on the efficacy of ethanol celiac plexus neurolysis in patients with operable pancreatic and periampullary adenocarcinoma
  3. Non-neoplastic Epithelial Cysts of the Pancreas: A Rare, Benign Entity
  4. Complex cystic lesions in the liver causing abdominal pain
  5. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells
  6. Overexpressing TNF-Alpha in Pancreatic Ductal Adenocarcinoma Cells and Fibroblasts Modifies Cell Survival and Reduces Fatty Acid Synthesis via Downregulation of Sterol Regulatory Element Binding Protein-1 and Activation of Acetyl CoA Carboxylase
  7. Does Resident Experience Affect Outcomes in Complex Abdominal Surgery? Pancreaticoduodenectomy as an Example
  8. Roscoe Reid Graham (1890 to 1948): a Canadian pioneer in general surgery.
  9. Grit: A marker of residents at risk for attrition?
  10. Intraoperative Pancreatoscopy: A Valuable Tool for Pancreatic Surgeons?
  11. Safety of perioperative aspirin therapy in pancreatic operations
  12. MCT4 Defines a Glycolytic Subtype of Pancreatic Cancer with Poor Prognosis and Unique Metabolic Dependencies
  13. When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery
  14. The HYSLAR trial: A prospective randomized controlled trial of the use of a restrictive fluid regimen with 3% hypertonic saline versus lactated ringers in patients undergoing pancreaticoduodenectomy
  15. Emergent pancreaticoduodenectomy: A dual institution experience and review of the literature
  16. Clinical Significance of Serum COL6A3 in Pancreatic Ductal Adenocarcinoma
  17. Extended pancreatectomy in pancreatic ductal adenocarcinoma: Definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS)
  18. Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)
  19. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer
  20. Dr. Seishu Hanaoka (1760-1835): surgeon, pharmacist, and anesthesiologist.
0